Drug
Midostaurin clinical trials
Also written PKC412, Rydapt, CGP 41251 and N-Benzoylstaurosporine.
- studies test it
- 33
- open now
- 2
- in phase 3
- 4
- first study started
- 2004
Keep track of what changes. Save the midostaurin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Other names
Combined with it in one product
Studies by the year they started
32 studies that test it; most in 2018 (6)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 1 |
| 2018 | 6 |
| 2019 | 3 |
| 2020 | 3 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 21
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 23
Novartis Pharmaceuticals (10) · Richard Stone, MD (2) · Technische Universität Dresden (2) · Stichting Hemato-Oncologie voor Volwassenen Nederland (1) · Alliance for Clinical Trials in Oncology (1) · Uma Borate (1) · National Cancer Institute (NCI) (1) · Brenda Cooper, MD (1)
Often tested with
Tested in the same studies.
Cytarabine (4) · Daunorubicin (3) · Azacitidine (3) · Decitabine (3) · Gemtuzumab (2) · Everolimus (1) · Nivolumab (1) · LGH-447 (1)
Studies
Open first, then newest update. How each study uses midostaurin is read from its arms, and is right about nine times in ten.
Testing it · 33
- Revumenib in Combination With 7+3 + Midostaurin in AMLRecruitingPhase 1Richard Stone, MDNCT06313437Written as Midostaurin
- Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)RecruitingPhase 1/2Technische Universität DresdenNCT04385290Written as MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO
- Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedPhase 3Alliance for Clinical Trials in OncologyNCT00651261Written as midostaurin
- A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AMLActive, not recruitingPhase 2Novartis PharmaceuticalsNCT03591510Written as Midostaurin
- Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid LeukemiaCompletedPhase 1Uma BorateNCT03900949Written as Midostaurin
- RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDSActive, not recruitingPhase 1Richard Stone, MDNCT00819546Written as PKC412
- A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AMLCompletedPhase 2Novartis PharmaceuticalsNCT03280030Written as Midostaurin
- Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor LeukemiaTerminatedPhase 2Niguarda HospitalNCT03686345Written as Midostaurin
- Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedPhase 2/3National Cancer Institute (NCI)NCT03092674Written as Midostaurin
- Induction Therapy for Patients With FLT3 Mutated Acute Myeloid LeukemiaWithdrawnPhase 1/2Guenther KoehneNCT04982354Written as Midostaurin
- Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS PatientsActive, not recruitingPhase 2Stichting Hemato-Oncologie voor Volwassenen NederlandNCT04097470Written as Midostaurin
- Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.CompletedPhase 3Novartis PharmaceuticalsNCT03379727Written as Midostaurin
- A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)CompletedPhase 3Novartis PharmaceuticalsNCT03512197Written as Midostaurin
- HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.TerminatedPhase 1Insel Gruppe AG, University Hospital BernNCT04496999Written as Midostaurin
- Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous LeukemiaCompletedPhase 1/2Brenda Cooper, MDNCT01093573Written as midostaurin
- Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell TransplantationTerminatedPhase 2University of JenaNCT03951961Written as Midostaurin
- PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic FunctionCompletedPhase 1Novartis PharmaceuticalsNCT01429337Written as Midostaurin
- Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AMLCompletedPhase 2Novartis PharmaceuticalsNCT01883362Written as Midostaurin
- PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedPhase 1Novartis PharmaceuticalsNCT00093600Written as midostaurin
- A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)CompletedPhase 1Novartis PharmaceuticalsNCT02078609Written as LGH447 + midostaurin
See all 33 studies that test midostaurin →
Given in every arm · 6 — midostaurin is usual care beside what is tested
- Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT02115295Written as Midostaurin
- AML Patients Bearing FLT3 Mutations Based on Peripheral Blast ClearanceRecruitingPhase 3Gruppo Italiano Malattie EMatologiche dell'AdultoNCT04174612Written as Midostaurin
- A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid LeukemiaCompletedPhase 1Jazz PharmaceuticalsNCT04075747Written as Midostaurin
- HDM201 Added to CT in R/R or Newly Diagnosed AMLWithdrawnPhase 1/2Novartis PharmaceuticalsNCT03760445Written as midostaurin
- PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)CompletedPhase 1/2Novartis PharmaceuticalsNCT00045942Written as PKC412
- Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid LeukemiaCompletedPhase 1Alison WalkerNCT01174888Written as midostaurin
As the comparator · 3 — what is tested is compared with midostaurin
- Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid LeukemiaCompletedPhase 2PrECOG, LLC.NCT03836209Written as Midostaurin
- Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AMLCompletedPhase 3Arog Pharmaceuticals, Inc.NCT03258931Written as Midostaurin
- A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive ChemotherapyActive, not recruitingPhase 3Stichting Hemato-Oncologie voor Volwassenen NederlandNCT04027309Written as Midostaurin
Codes
What other systems call midostaurin · ClinicalTrials.gg INT003432
- MeSH (NLM) C059539midostaurinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) ID912S5VONMIDOSTAURINConfirmed FDA, NLM, Wikidata
- RxNorm 1919083Confirmed FDA, Wikidata
- Wikidata Q6842945midostaurinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1872MidostaurinConfirmed FDA, Wikidata
- DrugBank DB06595One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C059539 | midostaurin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | ID912S5VON | MIDOSTAURIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1919083 | — | Confirmed FDA, Wikidata |
| Wikidata | Q6842945 | midostaurin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1872 | Midostaurin | Confirmed FDA, Wikidata |
| DrugBank | DB06595 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.